难治性免疫性血小板减少性紫癜患者应用小剂量利妥昔单抗联合IL-11治疗的临床效果探讨  

Clinical effect of small dose of rituximab combined with il-11 in patients with refractory immune thrombocytopenic purpura

作　　者：骆慧莎 陈汀劳 覃永亮 张雅西 LUO Huisha;CHEN Tinglao;QIN Yongliang;ZHANG Yaxi(Department of Hematology,Jiangmen People's Hospital in Guangdong Province,Jiangmen 529000,China;Department of Emergency,Jiangmen People's Hospital in Guangdong Province,Jiangmen 529000,China)

机构地区：[1]广东省江门市人民医院血液科,广东江门529000 [2]广东省江门市人民医院急诊科,广东江门529000

出　　处：《中国医药科学》2019年第3期213-216,共4页China Medicine And Pharmacy

摘　　要：目的探讨应用小剂量利妥昔单抗联合IL-11治疗难治性免疫性血小板减少性紫癜患者的临床效果。方法将2013年1月～2018年1月我院36例难治性免疫性血小板减少性紫癜患者,采用随机数字表法将其分为两组,其中对照组患者应用常规方法进行治疗,实验组在常规用药基础上,应用小剂量利妥昔单抗联合IL-11治疗,观察并比较两组患者术后临床疗效。结果经过不同药物治疗后,实验组难治性免疫性血小板减少性紫癜患者治疗总有效率(94.44%)明显高于对照组总有效率(61.11%),差异有统计学意义(P <0.05);实验组患者乏力、心房颤动、皮疹、感染不良反应发生率(11.11%)明显低于对照组不良反应发生率(50.00%),差异有统计学意义(P <0.05);随访一年,实验组患者该疾病复发率(5.56%)明显低于对照组该疾病复发率(38.89%),差异有统计学意义(P <0.05)。结论对难治性免疫性血小板减少性紫癜患者,应用小剂量利妥昔单抗,联合IL-11治疗,可有效提升血小板计数,缓解患者出现倾向,避免耐药性的产生,有助于患者疾病的恢复,提高患者生活质量。Objective To explore the clinical effect of small dose of rituximab combined with il-11 in patients with refractory immune thrombocytopenic purpura. Methods Thirty-six cases with refractory Immunologic Thrombocytopenic Purpura in our hospital from January 2013 to January 2018 were divided into two groups.The control group was treated with conventional methods.On the basis of conventional medication,the experimental group was treated with small dose of rituximab combined with IL-11.The clinical effects of the two groups were observed and compared. Results After treatment with different drugs, the total effective rate(94.44%)in the experimental group was significantly higher than that in the control group(61.11%) with statistical significance(P < 0.05).The incidence of adverse reactions(11.11%)in the experimental group was significantly lower than that in the control group(50.00%) with statistical significance(P < 0.05).After one-year follow-up,the recurrence rate of the disease in the experimental group(5.56%)was significantly lower than that in the control group(38.89%).The differences were statistically significant(P < 0.05). Conclusion For patients with refractory immune thrombocytopenic purpura,small dose of rituximab combined with il-11 treatment can effectively improve the platelet count,alleviate the tendency of patients,avoid the emergence of drug resistance,contribute to the recovery of the disease,and improve the quality of life of patients.

关 键 词：难治性 免疫性血小板减少性紫癜 利妥昔单抗 白细胞介素-11(IL-11) 

分 类 号：R558[医药卫生—血液循环系统疾病]